{"entity":{"id":"nct06801236","kind":"trial","name":"Phase 1 Study of ACE-232 to Treat Patients With Metastatic Castration-Resistant Prostate Cancer","aka":[],"tldr":"A phase 1 trial of ACE-232 run by Acerand Therapeutics (Hong Kong) Limited, now recruiting.","summary":"Phase 1 Study of ACE-232 to Treat Patients With Metastatic Castration-Resistant Prostate Cancer is a phase 1 interventional study registered as NCT06801236 by Acerand Therapeutics (Hong Kong) Limited, with 88 participants planned, started 2025-05-12. Conditions recorded: Prostate Cancer (Adenocarcinoma) and mCRPC (Metastatic Castration-resistant Prostate Cancer). Interventions recorded: ACE-232 tablets.","status":"recruiting","asOf":"2026-11-03","links":[{"label":"ClinicalTrials.gov NCT06801236","url":"https://clinicaltrials.gov/study/NCT06801236"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["prostate","prostate-mcrpc"],"sections":[],"technologies":[],"targets":[],"drugs":["ace-232"],"companies":["acerand-therapeutics"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06801236","phase":"1","setting":"A Phase 1 Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of ACE-232 in Patients With Metastatic Castration-Resistant Prostate Cancer (CRPC)","sponsor":"Acerand Therapeutics (Hong Kong) Limited","enrolled":88,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06801236/","neighbours":{"cancer":[{"id":"prostate-mcrpc","kind":"cancer","name":"Metastatic castration-resistant prostate cancer","route":"/cancers/prostate-mcrpc/"},{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/"}],"drug":[{"id":"ace-232","kind":"drug","name":"ACE-232","route":"/drugs/ace-232/"}],"company":[{"id":"acerand-therapeutics","kind":"company","name":"Acerand Therapeutics","route":"/companies/acerand-therapeutics/"}]}}